PBMs are inflating the cost of generic drugs. They must be reined in

hese are not comfortable days in Washington for pharmacy benefit managers, the highly consolidated group of intermediaries that sit astride the drug supply chain. The Federal Trade Commission and Capitol Hill want to know how the PBMs’ arcane business practices impact pharmaceutical costs. This is welcome news for just about everyone else, including consumers of generic drugs.


Read the full piece >